Therapy Areas: AIDS & HIV
Initial Results of Dose-escalation Phase of Trial of NKTR-214 in Combination with OPDIVO (nivolumab) Presented at SITC 2017
13 November 2017 - - San Francisco, California-based research-based development stage biopharmaceutical company Nektar Therapeutics (NASDAQ: NKTR) and New York, New York-based biopharmaceutical company Bristol-Myers Squibb (NYSE: BMY) have released initial results of the dose-escalation phase of the the PIVOT-02 Phase 1/2 Study, the companies said.
The PIVOT-02 Phase 1/2 Study is designed to evaluate the combination of Bristol-Myers Squibb's Opdivo (nivolumab) with Nektar's investigational medicine, NKTR-214.
Opdivo is a PD-1 immune checkpoint inhibitor designed to overcome immune suppression.
NKTR-214 is an investigational immuno-stimulatory therapy designed to expand and activate specific cancer-fighting T cells and natural killer cells directly in the tumor micro-environment and increase expression of cell-surface PD-1 on these immune cells.
The initial results reported in an oral session at the SITC meeting provided both safety and efficacy data for 38 patients enrolled in the ongoing trial.
Nektar and Bristol-Myers Squibb entered into a clinical collaboration in September of 2016 to evaluate the potential for the combination of Opdivo and NKTR-214 to show improved and sustained efficacy and tolerability above the current standard of care.
Bristol-Myers Squibb and Nektar are equally sharing costs of the combined therapy trials. Nektar maintains its global commercial rights to NKTR-214.
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers chemically-synthesized drug and biologic in various therapeutic areas, such as oncology; cardiovascular; immunoscience; and virology comprising human immunodeficiency virus infection (HIV).
Nektar Therapeutics is a research-based development stage biopharmaceutical company whose mission is to discover and develop innovative medicines to address the unmet medical needs of patients. Its R and D pipeline of new investigational medicines includes treatments for cancer, auto-immune disease and chronic pain. Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India.
Login
Username:

Password: